The U.S. FDA granted Edap Tms SA breakthrough device designation for its Focal One system to treat deep infiltrating rectal endometriosis. The company believes that the Focal One high intensity focused ultrasound technology can offer relief to the thousands of women suffering from the debilitating condition.
A team of Johns Hopkins University researchers have filed for patent protection of a system and method to determine patient prioritization for triage during mass trauma events. The system and method may continuously monitor patient parameters to determine patient prioritization over time, which may improve the speed, quantity, and efficacy of life-saving interventions.
Royal Philips NV received a second round of funding from the Bill & Melinda Gates Foundation to speed adoption of artificial intelligence (AI) algorithms on the Lumify hand-held ultrasound device, bringing its total commitment to the project designed to reduce maternal mortality to $60 million.
The FDA’s recent clearance of Ultrasight Inc.’s artificial intelligence (AI)-powered ultrasound guidance technology will allow for the widespread detection of heart diseases in the U.S. and ease bottlenecks in the healthcare system that currently restrict access for many people, Davidi Vortman, CEO of Ultrasight told BioWorld. Ultrasight’s software helps medical professionals without sonography experience acquire cardiac ultrasound images at the point of care in multiple settings.
Current Surgical Inc. secured $3.2 million in a seed funding round to support development of its surgical needle platform to precisely destroy unresectable tumors. True Ventures led the round with participation from 1517 Fund and Scifounders.
Hemosonics LLC said it was recently awarded U.S. FDA clearance for a new hemostasis test cartridge assay it said significantly expands the indications for clinical use of its existing Quantra system to now also include trauma and liver transplantation procedures. The expanded Quantra hemostasis system with its QStat cartridge will add to capabilities of the system’s QPlus cartridge assay already established in the point-of-care and lab-based, whole blood hemostasis testing market.
Transition ultrasound startup QT Imaging Inc. is poised to go public via a merger with Gigcapital5 Inc., a special purpose acquisition company (SPAC), in a deal that puts the equity value of the combination at $151 million. The combined company, QT Imaging Holdings Inc. will be traded on the NYSE under the ticker symbol QTI.
Sonothera Inc. reeled in $60.75 million in a series A financing led by Arch Venture Partners. The funds are earmarked for the continued development of Sonothera’s ultrasound-guided, nonviral, gene therapy platform and treatments.
A new ultrasound-based technique has been developed to overcome the shortcomings of conventional X-ray mammography in screening younger women whose breast density is high.
Delphinus Medical Technologies Inc. raised $30.4 million in a series D fundraising round to support worldwide commercialization of its Softvue 3D whole breast ultrasound tomography system. Both new and existing investors kicked in funds including Arboretum Ventures, Beringea, North Coast Technology Investors, Venture Investors, Hopen Life Science Ventures and Waycross Ventures.
